New hope for rare sinus cancer: combined therapy shows promise
NCT ID NCT07449949
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment plan for adults with a rare cancer of the nasal and sinus cavities called rhabdomyosarcoma. The plan involves chemotherapy and radiation before and after surgery. The goal is to see if this approach can shrink tumors and improve survival. The study will enroll 43 people who have not been treated before.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vincristine, Actinomycin D, Epirubicin, Cisplatin, Cyclophosphamide, and radiation therapy
- What this could lead to
- If successful, this could provide a standard treatment approach for a rare cancer that currently lacks established guidelines.
- What could go wrong
- This is a small, single-arm study with only 43 participants, so results may not apply to all patients. The treatment involves strong chemotherapy and radiation, which can cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
EENT hospital of Fudan University
Shanghai, China, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.